Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 03:53:33 UTC |
---|
Update Date | 2021-09-26 23:00:10 UTC |
---|
HMDB ID | HMDB0249380 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Brigatinib |
---|
Description | Brigatinib belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. Brigatinib is a very strong basic compound (based on its pKa). Brigatinib is manufactured by ARIAD Pharmaceuticals, Inc (NASDAQ: ARIA) which is focused on rare cancers. Additionally, the T790M “gatekeeper” mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors. Brigatinib acts as both a anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. ARIAD is now an indirect wholly owned subsidiary of Takeda. A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy. While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native (endogenous or unmutated) EGFR. Brigatinib is the INN.In Bangladesh it is under the trade name Briganix. Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. This compound has been identified in human blood as reported by (PMID: 31557052 ). Brigatinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Brigatinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1 InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34) |
---|
Synonyms | Value | Source |
---|
AP26113 | ChEMBL | AP-26113brigatinib | ChEMBL |
|
---|
Chemical Formula | C29H39ClN7O2P |
---|
Average Molecular Weight | 584.1 |
---|
Monoisotopic Molecular Weight | 583.2591382 |
---|
IUPAC Name | 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine |
---|
Traditional Name | 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine |
---|
CAS Registry Number | Not Available |
---|
SMILES | COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1 |
---|
InChI Identifier | InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34) |
---|
InChI Key | AILRADAXUVEEIR-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Piperidines |
---|
Sub Class | Phenylpiperidines |
---|
Direct Parent | Phenylpiperidines |
---|
Alternative Parents | |
---|
Substituents | - Phenylpiperidine
- Aminophenyl ether
- Methoxyaniline
- Anisole
- Phenoxy compound
- Phenol ether
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Aniline or substituted anilines
- Methoxybenzene
- Alkyl aryl ether
- 4-aminopiperidine
- Aminopyrimidine
- Halopyrimidine
- Phenylphosphine
- N-methylpiperazine
- N-alkylpiperazine
- Pyrimidine
- Piperazine
- Imidolactam
- Benzenoid
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- 1,4-diazinane
- Heteroaromatic compound
- Organophosphine oxide
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Secondary amine
- Ether
- Organic oxide
- Amine
- Organohalogen compound
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Organophosphorus compound
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Brigatinib,1TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C | 4669.5 | Semi standard non polar | 33892256 | Brigatinib,1TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C | 4391.2 | Standard non polar | 33892256 | Brigatinib,1TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C | 5602.5 | Standard polar | 33892256 | Brigatinib,1TMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1 | 4639.9 | Semi standard non polar | 33892256 | Brigatinib,1TMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1 | 4545.4 | Standard non polar | 33892256 | Brigatinib,1TMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1 | 5550.3 | Standard polar | 33892256 | Brigatinib,2TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1)[Si](C)(C)C | 4512.2 | Semi standard non polar | 33892256 | Brigatinib,2TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1)[Si](C)(C)C | 4418.5 | Standard non polar | 33892256 | Brigatinib,2TMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C)=N1)[Si](C)(C)C | 5223.6 | Standard polar | 33892256 | Brigatinib,1TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C(C)(C)C | 4817.9 | Semi standard non polar | 33892256 | Brigatinib,1TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C(C)(C)C | 4603.2 | Standard non polar | 33892256 | Brigatinib,1TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)[Si](C)(C)C(C)(C)C | 5624.3 | Standard polar | 33892256 | Brigatinib,1TBDMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1 | 4781.9 | Semi standard non polar | 33892256 | Brigatinib,1TBDMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1 | 4761.2 | Standard non polar | 33892256 | Brigatinib,1TBDMS,isomer #2 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1NC1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1 | 5579.1 | Standard polar | 33892256 | Brigatinib,2TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1)[Si](C)(C)C(C)(C)C | 4823.9 | Semi standard non polar | 33892256 | Brigatinib,2TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1)[Si](C)(C)C(C)(C)C | 4814.8 | Standard non polar | 33892256 | Brigatinib,2TBDMS,isomer #1 | COC1=CC(N2CCC(N3CCN(C)CC3)CC2)=CC=C1N(C1=NC=C(Cl)C(N(C2=CC=CC=C2P(C)(C)=O)[Si](C)(C)C(C)(C)C)=N1)[Si](C)(C)C(C)(C)C | 5291.5 | Standard polar | 33892256 |
| Show more...
---|